Plain-English translation of NCT04986423 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new medication, works better when combined with (a prostate cancer drug you may already know about) compared to alone. The study focuses on men whose prostate cancer has progressed despite previous treatment with abiraterone. Researchers want to see if this new combination can help control the cancer better.
Prostate cancer can become resistant to standard treatments over time, meaning the medications stop working as well as they did initially. This medication is being tested to see if it can overcome that resistance and give men more options when their cancer stops responding to earlier treatments.
You likely qualify if…
You likely don't qualify if…
You will take orally (by mouth) every day for 21 days before the study officially begins, to let the medication build up in your system. After that, depending on which group you're randomly assigned to, you'll either continue taking alone or add the new medication to your daily routine. The study is organized in 28-day cycles, and you'll have regular visits to have your blood tested and your cancer monitored to see how well the treatment is working.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States